Neurofibromatosis type 1 (NF1) is caused by heterozygous mutation in the NF1 gene. NF1 is one of the most common human genetic diseases. However, the overall genotype-phenotype correlation has not been known, due to a wide spectrum of genotypic and phenotypic heterogeneity. Here we describe the detailed clinical and genetic features of 427 Korean NF1 patients from 389 unrelated families. Long range PCR and sequencing of genomic DNA with multiplex ligation-dependent probe amplification analysis identified 250 different NF1 mutations in 363 families (93%), including 94 novel mutations. With an emphasis on phenotypes requiring medical attention (classified and termed: NF1 + ), we investigated the correlation of NF1 + and mutation types. NF1 + was more prevalent in patients with truncating/splicing mutations and large deletions than in those with missense mutations (59.6%, 64.3% vs. 36.6%, p = 0.001). This difference was especially significant in the patients younger than age 19 years. The number of items in NF1 + was a higher in the former groups (0.95 ± 0.06, 1.18 ± 0.20 vs. 0.56 ± 0.10, p = 0.002). These results suggest that mutation types are associated not only with higher prevalence of severe phenotypes in NF1 but also with their earlier onset.
Introduction
Neurofibromatosis type 1 (NF1; OMIM#162200) is caused by loss of function mutation in the NF1 gene on chromosome 17q11.2 [1] . NF1 encodes neurofibromin, a Ras-specific guanosine triphosphatase (GTPase) activating protein that converts active GTP-bound Ras to inactive GDPbound Ras. As neurofibromin serves as a negative regulator of the Ras-mitogen activated protein kinase signaling pathway, which controls cell growth and proliferation, the inactivation of neurofibromin leads to the hyperactivation of RAS and its downstream mediators and contributes to tumor formation [2, 3] .
The main manifestations of NF1 are café au lait macules (CALMs), axillary and/or inguinal freckling, cutaneous and/ or plexiform neurofibromas, and Lisch nodules in the iris. Additional features include intellectual disabilities, learning difficulties, short stature, vasculopathy, bony dysplasia, optic gliomas, and an increased risk for benign and malignant nervous system tumors [4] . The NIH criteria for NF1 results in most diagnoses [5] ; however, clinical diagnosis may not be feasible in certain patients, especially in youngage subjects, since the frequency of the clinical features of NF1 increase with age, as well as a wide range of phenotypic heterogeneity among patients [6] .
The genetic testing of NF1 would help to clarify the diagnostic process; however, genetic testing is difficult for a number of reasons: NF1 is a large gene, spanning over 275 kb in the genome and containing 57 constitutive exons and at least three alternatively spliced exons. As there is no mutational hotspot, every coding exon must be analyzed. A considerable number of splicing mutations are caused by deep intronic splicing mutations that are not usually detected by routine DNA analysis [7, 8] . In addition, 15 highly homologous NF1 pseudogenes exist in the human genome, which further complicate the accurate molecular analyses of the NF1 gene. As a result, the direct sequencing analysis of genomic DNA alone has detected only mutations in only about 60% of patients with NF1 [9, 10] . With a multistep mutation detection protocol that includes analyses of both genomic DNA and cDNA with testing for whole gene or exon copy number changes, over 95% of patients with NF1 can be diagnosed; however, this test is labor intensive and fiscally burdensome [11] [12] [13] .
In the current study, we evaluated the clinical and genetic characteristics of a large Korean NF1 cohort. The NF1 mutation was identified using long range PCR and multiplex ligation-dependent probe amplification (MLPA) analysis of genomic DNA, which is comparable to cDNA analysis in terms of the mutation detection rate. Finally, in order to better stratify the overall genotype-phenotype correlation in our patient cohort, we correlated the phenotypes based on the necessity of medical attention and the relation to the NF1 mutation molecular profile.
Patients and methods

Patients
This study included 427 Korean patients with NF1 from 389 independent families with clinically diagnosed or suspected NF1 and who underwent molecular genetic testing between June 2012 and May 2018 at the Department of Medical Genetics, Asan Medical Center Children's Hospital, Seoul, Korea. This study was approved by the Institutional Review Board at the Asan Medical Center, and appropriate written informed consent was obtained from each patient or the parents of the patient.
Clinical data
The following data were reviewed retrospectively: sex, age at evaluation, mode of inheritance, clinical and radiological manifestations, and molecular analysis. The clinical data were collected at the time of mutation analysis. The patients with missing data for a specific feature were excluded from the genotype-phenotype analysis.
The diagnosis of NF1 was based on the NIH diagnostic criteria [5] . Considering the wide range of phenotypic heterogeneity of NF1, for the genotype-phenotype correlation analysis, we denoted the phenotypes requiring medical attention as "NF1-plus" (NF1 + ). In NF1 + , widely spread diffuse cutaneous neurofibromas, learning disabilities, autism, seizure, cardiac abnormalities, hearing defect, optic pathway glioma, severe plexiform neurofibromas (>3 cm in diameter, disfigurement, accompanying pain, bony destruction, or located para-aortic area), brain tumors, nerve root tumors, malignant peripheral nerve sheath tumors, moyamoya disease, and bony dysplasia were included. Short stature was defined as a height >2.0 below the standard deviation score compared with the normative data obtained from Korean references [14] .
Molecular analysis
The genomic DNA was isolated from peripheral blood leukocytes using a Gentra Puregene blood kit (Qiagen, Hilden, Germany). Sanger sequencing was performed for all coding 57 exons and exon-intron boundaries of NF1 (NM_00267.3). The homologous sequence domains of NF1 were amplified with a range of 6-13 kb in size using five NF1-specified primer sets (exons 9, 11, 13, 18-20, 29, and 30) to exclude cysteine/serine-rich domain (CSRD), GTPase-activating protein-related domain (GRD), and Sep14p pseudo-sequence regions (Table S1 ). Nested PCRs were carried out in the five long-PCR products using exonby-exon primers of the NF1 gene. Long PCR was performed using GoTaq Long PCR Master Mix (Progema, Madison, WI, USA). Direct sequencing was performed on a ABI 3130 genetic analyzer (Applied Biosystems, Foster City, CA, USA) using a BigDye Terminator cycle sequencing kit (Applied Biosystems).
MLPA analyses were carried out using SALSA MLPA Probemix P081 and P082 (MRC Holland, Amsterdam, The Netherlands) to detect the deletion and duplication of NF1. SALSA MLPA Probemiex P122 (MRC Holland) was used to determine the type of NF1 microdeletion in the patients with total NF1 deletion.
For RNA analysis, blood samples were collected directly into PAXgeneTM blood RNA tubes and total cellular RNA was extracted from the samples with the PAXgeneTM blood RNA kit (PreAnalytiX, Hombrechtikon, Switzerland) according to the manufacturer's protocol. The cDNA synthesis was performed using a PrimeScript II 1st Strand cDNA Synthesis kit (TaKaRa Bio, USA) with random hexanucleotides as primers. The cDNAs were amplified using a PrimeSTAR GXL DNA polymerase (TaKaRa Bio, USA) with the primers for NF1 gene (Table S2 ). The amplified products were separated on a 1% agarose gel and directly sequenced. Sequence analysis was performed using the same primers used in PCR and BigDye Terminatore V3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA).
The pathogenicity of mutations was assessed by in silico prediction analyses, such as PolyPhen-2 (http://genetics.bw h.harvard.edu/pph2) and SIFT (http://sift.jcvi.org). Variants identified were classified according to the American College of Medical Genetics and Genomics [15] .
Statistical analysis
Two-tailed Fisher's exact test was used to compare categorical variables, where a p value < 0.05 was considered as statistically significant. All statistical analyses were performed with SPSS version 21 for Windows (SPSS Inc., Chicago, IL, USA). Watson syndrome is characterized by multiple café au lait spots, pulmonary stenosis, intellectual disability, and short stature. In this study, three patients had structural congenital heart disease, valvular aortic stenosis (case no. 53), pulmonary stenosis (case no. 56), and perimembranous ventricular septal defect (case no. 246).
Results
Demographic and clinical characteristics of the patients
Patients with NF1 experience a life-long clinical course and phenotypes progress with aging. In this respect, the detailed clinical and radiological findings at evaluation were compared among three different age groups; prepubertal age (<8 years), adolescent age (8-18 years), and adulthood (>18 years). Because of the wide range of phenotypic diversity, we focused on the existence of our classification of NF1 + in each subject. Most clinical and radiological manifestations and NF1 + became more prevalent in the age group 8-18 years and over 18 years (Table 1 and Fig. 1a ). On the other hand, attention deficit/hyperactive disorder (ADHD) and FASI were less frequent in adult patients ( Table 1 , p < 0.000).
Regarding the mode of NF1 inheritance, cutaneous neurofibromas, widely spread cutaneous neurofibromas, plexiform neurofibromas, vertebral dysplasia, and NF1 + were more prevalent in familial cases than in sporadic cases ( Table 1 and Fig. 1b ).
Between male and female patients, plexiform neurofibromas, severe plexiform neurofibromas, and brain tumors were frequently reported in male patients ( Table 1 and Fig. 1c, d ). In addition, cutaneous neurofibromas and brain tumors were more prevalent in male patients at 8-18 years (71.4% vs. 45.5%, p = 0.033, 32.1% vs. 0.0%, p = 0.003, respectively) and the plexiform neurofibromas in the male patients over 18 years (73.6% vs. 40.8%, p = 0.001).
Molecular characteristics and mutation detection rate using long range PCR and MLPA analysis
The long range PCR and sequencing of gDNA identified NF1 mutations in 315/389 families (81.0%). Among 83 families without a point mutation in the coding region of NF1, MLPA analysis identified exonic NF1 deletions in 24 families (24/389, 6.2%). Overall, 339 families (87.1%) were genetically diagnosed using long range genomic PCR and MLPA methods.
A total of 250 different mutations were identified in these 339 families. The distribution of NF1 mutations are summarized in Fig. 2 . Frameshift mutations were the most (Fig. 2a ). The mutation spots were spread out along the coding region of the NF1 gene, except for a relatively small number of mutations that were found in the 3′ terminal region (exons 50-57) (Fig. 2b) . Thirty-eight mutations (15.2%) were recurrent mutations; the most common mutation was the NF1 whole gene deletion (n = 14/339, 4.1%), followed by c.1756_1759del (p.T586fs, n = 11/339, 3.2%), c.4537C > T (p.R1513*, n = 9/339, 2.7%), c. 6792C > A (p.Y2264*, n = 6/339, 1.8%), and c.1466A > C (p.Y489C, n = 5/339, 1.5%). Among the 250 mutations, 94 (37.6%) mutations from 98 families were not previously reported. Thirty-two mutations were confirmed by family member testing and eight mutations were confirmed by cDNA sequence analysis (Table S3) .
A total of 24 families had large exonic deletions. The complete NF1 gene deletion was found in 14 families (58.3%) and exon 13-57 deletion in 2 families (8.3%). Exon 3 deletion, exon 30-31 deletion, 5'UTR and exon 1 deletion, exon 1-6 deletion, exon 1-3 deletion, exon 3-8 deletion, exon 13-57 deletion, and exon 38-57 deletion were found in 1 family each (4.2%). Of the 14 families with a complete NF1 gene deletion, 11 families were found to contain a range of deleted regions, as previously categorized [16] ; nine families had the type-1 NF1 microdeletion encompassing 1.4-Mb including 14 protein-coding genes and four microRNA genes (chromosome 17q11.2 deletion, 1.4 Mb; OMIM #613675), one family had the type-2 NF1 microdeletion encompassing 1.2-Mb associated with 13 protein-coding genes, and one family had the type-3 NF1 microdeletion spanning 1.0-Mb leading to hemizygosity for nine protein-coding genes.
Genotype and phenotype correlations
The clinical and radiological findings at evaluation were compared with the types of mutations (missense mutations/ inframe deletions, truncating/splicing mutations, and large deletions, Table 2 ) to determine if trends were evident. The NF1 + was more prevalent in patients with truncating/splicing mutations and large deletions than in those with missense mutations, and this difference was also significant in patients younger than 8 years and over 18 years (Table 2 and Fig. 3a ). The number of items in NF1 + was significantly higher in the patients with truncating/splicing mutations or large deletions compared with those with missense mutations/inframe deletions (0.95 ± 0.06 in truncating/splicing mutations and 1.18 ± 0.20 in large deletions vs. 0.56 ± 0.10 in missense mutations/ inframe deletions, p = 0.002, Fig. 3b ). In addition, axillary freckling (71.3% in truncating/splicing mutations, 84.6% in large deletions, vs. 59.1% in missense mutations/inframe deletions, p = 0.039) and widely spread cutaneous neurofibromas (41.9% in truncating/ splicing mutations and 58.3% in large deletions vs. 26.5% in missense mutations/inframe deletions, p = 0.024) were more common in these groups. Learning disabilities were more prevalent in large deletions (29.6% in large deletions vs. Fig. 1 The frequency of clinical manifestations of NF1 according to age, inheritance, and sex. NF1 + is defined as phenotypes requiring medical attention, which include widely spread diffuse cutaneous neurofibromas, learning disabilities, autism, seizure, cardiac abnormalities, hearing defect, optic pathway glioma, severe plexiform neurofibromas (>3 cm in diameter, disfigurement, accompanying pain, bony destruction, or located para-aortic area), brain tumors, nerve root tumors, malignant peripheral nerve sheath tumors, moyamoya disease, and bony dysplasia 9.4% in missense mutations/inframe deletions and 8.5% in truncating/splicing mutations, p = 0.008), with a significant difference in the age groups of 8-18 years (60.0% in large deletions vs. 21.4% in missense mutations/inframe deletions and 11.1% in truncating/splicing mutations, p = 0.027) and over 18 years (33.3% in large deletions vs. 4.3% in missense mutations/inframe deletions and 5.9% in truncating/splicing mutations, p = 0.015).
A total of 12 patients had NF1 mutations involving the cysteine/serine-rich domain (CSRD), 93 patients involving the GRD, and 126 patients involving both domains. There were no significant differences in the prevalence of the phenotypes, including NF1 + , among the domains of NF1 mutations.
Discussion
NF1 is one of the most common genetic diseases, affecting 1 in 3000 people. However, due to the wide range of phenotypic heterogeneity and age-related disease progress, it is one of the most difficult genetic conditions to diagnose and provide the appropriate genetic counseling. The prediction and long-term prognosis of diagnosed young-aged patients is particularly challenging.
To fill this diagnostic gap, we focused on phenotypes requiring medical attention and categorized these into a phenotypic subgroup that we termed NF1 + , which was analyzed for groups of different ages, sexes, and mutations. The subgroup analysis provided several important findings with regards to the disease course and the correlation between genotype and phenotype. NF1 + was found in 54.9% of patients in our cohort. As an age-related condition, NF1 + became more prevalent in older patients, whereas ADHD or FASI became less prevalent. In terms of inheritability, 70% of our patients were sporadic cases, and NF1 + was less prevalent in sporadic than in familial cases. Certain phenotypes in NF1 + , such as severe plexiform neurofibromas or brain tumors, tended to be more prevalent in male than female patients. Although a reason for the phenotypic differences in terms of inheritability and sex was not found, one plausible explanation for a less severe phenotype in sporadic cases is the possibility that certain sporadic cases with NF1 mutations are somatic mosaicism.
The genotype-phenotype correlation is an important finding for the prediction of the disease course, and our study contributes significantly to a better understanding of this. Since about 85% of NF1 mutations were unique to a single individual or family without mutation hotspots, the correlation was assessed mainly based on the mutation types. Notably, NF1 + was more prevalent in patients with truncating/splicing mutations and large deletions than in those with missense mutations. This tendency was consistent in the different age subgroups (<8 years, 8-18 years, and >18 years), but especially significant in the young-age groups (<19 years). In addition, the number of items in NF1 + was higher in patients with truncating/splicing mutations and large deletions than missense mutations. These findings suggest that NF1 patients with truncating/ splicing mutations and large deletions are at greater risk of severe manifestations and their earlier onset.
A number of studies have previously evaluated the impact of mutation type on the NF1 phenotype, however, they did not detect any obvious correlation, especially with regards to the severe phenotypes [17, 18] . In the French cohort with 439 patients with NF1, patients with truncating mutations were found to have a greater incidence of Lisch nodules and a large number of CALMs [11] . Excluding the aforementioned mutation types, few genotype-phenotype correlations have been previously reported. Large deletions of the NF1 region have been previously associated with a more severe phenotype, particularly with regards to facial dysmorphisms and learning disabilities, which correlates with our results [19, 20] . Regarding intragenic NF1 mutations, one inframe deletion, c.2970_2972delAAT, which has been previously associated with a milder phenotype without cutaneous neurofibromas, was found in a 0.8-yearold female patient (case no. 168) who presented multiple CALMs and axillary freckling but no other manifestations [21] . Any missense mutations affecting codon 844-848 is associated with a severe phenotype; plexiform neurofibromas, symptomatic spinal neurofibromas, optic pathway gliomas, and skeletal abnormalities are more prevalent [22] . In our cohort, two patients had missense mutations affecting codons 844-848. A 12-year old male patient (case no. 137) with p.L847P showed CALMs, axillary freckling, cutaneous and plexiform neurofibromas, and short stature. The p.G848R mutation was identified in 10.6-year-old male patient (case no. 435) who had CALMs, widespread cutaneous neurofibromas, learning disabilities, ADHD, multiple spinal cord tumor lesions, and scoliosis (Table S3 ). Missense variants affecting Arg1809 are associated with multiple café au lait spots and Noonan-like features [23, 24] .
In our study, there were no significant genotype-phenotype correlations according to the functional domains, same as in a previous study [25] . Neurofibromin, a Ras-specific GTPaseactivating protein (Ras-GAP), is a large multidomain protein that downregulates the biological activity of Ras by accelerating the hydrolysis of Ras-bound GTP. The catalytic Ras-GAP activity is present in a central portion of neurofibromin, the GRD. The Sec14 and pleckstrin homology domain is also required for NF1 to function as a Ras-GAP by the correct spatial localization of neurofibromin [26, 27] . Another domain comprises the CSRD, indicative of ATP binding and potential cAMP-dependent protein kinase (PKA) recognition sites [10] .
The NF1 mutations display almost complete penetrance after childhood, but diverse clinical expression ranges from mild CALMs to life-threating complications at young age. In five families of our study, NF1 + was noted only in the children (family nos. 92 and 190) or younger siblings (family nos. 214, 225, and 241) but not in their parents or elder siblings. The variability of expression of NF1 has been explained by germline modifying genes, epigenetic modification, postzygotic mutations, second-hit somatic mutation, and environmental agents [28] .
The genetic testing of NF1 provides a confirmatory diagnosis to patients in which NF1 is suspected and, in particular, when the phenotypes do not fulfill the NIH diagnostic criteria. In our study, NF1 was confirmed in patients (34/35, 97 .1%) by genetic testing. We employed a combination of long range PCR and MLPA analysis for genomic DNA to obtain a mutation detection rate (87.2%) Fig. 3 a The prevalence of NF1 + according to the different mutation types. b The number of items included in NF1 + Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types that was comparable to the results of cDNA with MLPA analysis (~95%). This rate is higher than with gDNA alone (~63%) and comparable to targeted gDNA analysis using next-generation sequencing (~92%) [9, 10, [29] [30] [31] . A higher detection rate could be achieved by cDNA analysis to detect deep intronic variations affecting the splicing process [11] [12] [13] . Moreover, in sporadic cases with somatic NF1, the affected tissues should be evaluated to identify the pathogenic mutation. In addition, among 48 patients who did not have a pathogenic NF1 mutation, nine patients had only skin pigmentary lesions without neurofibromas or other tumors. These patients have a possibility of Legius syndrome caused by SPRED1 mutations, which account for about 2% of our patients fulfilling the NIH diagnostic criteria [32] .
The prevalence of most NF1 clinical features in our report was similar to previous reports [33] [34] [35] [36] . However, the prevalence of plexiform neurofibromas (43.8%) was higher in our report; in our study, over half of the patients (51.9%) were evaluated using whole body MRI, which revealed asymptomatic internal plexiform neurofibromas. Cognitive and behavioral deficits, which affect~80% of children with NF1, are the most common complications of NF1. Up to 40% of patients with NF1 present learning disabilities and/or cognitive impairment. In addition,~38% of children with NF1 have ADHD and 21-40% of children with NF1 have autism spectrum disorder [37] [38] [39] [40] [41] . In our study, the prevalence of learning disabilities, attention deficit, and autism (9.8% (38/386), 7.0% (27/383), and 0.2% (1/385), respectively) were likely underestimated as these were assessed based on patient self-reporting.
Our study contained a certain limitations. Given the retrospective nature of this study, there were missing or incomplete data. In addition, using the gDNA sequencing approach could result in misclassification of the mutation type in missense and nonsense mutations, since some missense and nonsense mutations lead to missplicing [7, 11, 12, 42] . Nevertheless, the findings of this study will help to improve our overall understanding of the correlation between genotype phenotype in patients with NF1.
In conclusion, to the best of our knowledge, this study is the first to correlate mutation type with phenotype severity in NF1, a common human genetic condition. A longer-term follow-up analysis of a large patient cohort will provide valuable information and further our understanding of the nature of NF1 and the contribution of NF1 genotypes.
